Immunomodulating drugs for chronic lymphocytic leukaemia

Lancet Oncology

Volumn 7, Issue 6, 2006, Pages 480-488

  Chanan Khan, Asher ^a   Porter, Carl W ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 AMINO 1,3 DIHYDRO 1,3 DIOXO 2H ISOINDOL 2 YL)GLUTARIMIDE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOKINE; DEXAMETHASONE; FLUDARABINE; IMMUNOMODULATING AGENT; LENALIDOMIDE; MONOCLONAL ANTIBODY; RITUXIMAB; THALIDOMIDE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; B LYMPHOCYTE; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DISEASE EXACERBATION; DIZZINESS; DROWSINESS; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG FEVER; EFFECTOR CELL; ERYTHEMA; FATIGUE; FOOT EDEMA; HUMAN; HYPOTENSION; IMMUNE RESPONSE; INFECTION; LEG EDEMA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MICROENVIRONMENT; MOLECULAR CLONING; MUSCLE WEAKNESS; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; NUCLEIC ACID PROBE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SEDATION; SIDE EFFECT; THROMBOCYTOPENIA; TUMOR CELL; VENOUS THROMBOEMBOLISM;

AGED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COMBINED MODALITY THERAPY; CYTOKINES; DOWN-REGULATION; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOCYTE COUNT; MIDDLE AGED; THALIDOMIDE;

EID: 33744482623     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)70723-9     Document Type: Review

References (60)

1. Rai K., and Chiorazzi N. Determining the clinical course and outcome in chronic lymphocytic leukemia. N Engl J Med 348 (2003) 1797-1799
2. van Kooten C., Rensink I., Aarden L., and van Oers R. Cytokines and intracellular signals involved in the regulation of B-CLL proliferation. Leuk Lymphoma 12 (1993) 27-33
3. Orsini E., and Fao R. Cytokines and soluble molecules in CLL. In: Fauget G. (Ed). Chronic lymphocytic leukemia (2005), Humana Press, New Jersey 123-142
4. Trentin L., Zambello R., Agostini C., et al. Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia. Blood 84 (1994) 4249-4256
5. Gorgun G., Holderried T., Zahrieh D., et al. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 115 (2005) 1797-1805
6. Rai K., Sawitsky A., Cronkite E., et al. Clinical staging of chronic lymphocytic leukemia. Blood 46 (1975) 219-234
7. Binet J., Auquier A., Dighiero G., et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 48 (1981) 198-206
8. Byrd J., Peterson B., Piro L., et al. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia 17 (2003) 323-327
9. Keating M., O'Brien S., Lerner S., et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92 (1998) 1165-1171
10. Rai K., Peterson B., Appelbaum F., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 343 (2000) 1750-1757
11. Keating M., Kantarjian H., O'Brien S., et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia. J Clin Oncol 9 (1991) 44-49
12. Byrd J., Gribben J., Peterson B., et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. J Clin Oncol 24 (2006) 437-443
13. Hillmen P. Advancing therapy for chronic lymphocytic leukemia-the role of rituximab. Semin Oncol 31 suppl 2 (2004) 22-26
14. Nabhan C. The emerging role of alemtuzumab in chronic lymphocytic leukemia. Clin Lymphoma Myeloma 6 (2005) 115-121
15. McCune S., Gockerman J., Moore J., et al. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma 43 (2002) 1007-1011
16. Faderl S., Coutre S., Byrd J., et al. The evolving role of alemtuzumab in management of patients with CLL. Leukemia 19 (2005) 2147-2152
17. Keating M., Coutre S., Rai K., et al. Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin Lymphoma 4 (2004) 220-227
18. Lin T., Lucas M., and Byrd J. Rituximab in B-cell chronic lymphocytic leukemia. Semin Oncol 30 (2003) 483-492
19. Byrd J., Peterson B., Morrison V., et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 101 (2003) 6-14
20. Keating M., O'Brien S., Albitar M., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23 (2005) 4079-4088
21. Meinhardt G., Wendtner C., and Hallek M. Molecular pathogenesis of chronic lymphocytic leukemia: factors and signaling pathways regulating cell growth and survival. J Mol Med 77 (1999) 282-293
22. Kay N., Bone N., Tschumper R., et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 16 (2002) 911-919
23. Caligaris-Cappio F., and Hamblin T. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 17 (1999) 399-408
24. Burger J., Burger M., and Kipps T. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood 94 (1999) 3658-3667
25. Kay N. The angiogenic status of B-CLL B cells: role of the VEGF receptors. Leuk Res 28 (2004) 221-222
26. Mainou-Fowler T., Miller S., Proctor S., and Dickinson A. The levels of TNF alpha, IL4 and IL10 production by T-cells in B-cell chronic lymphocytic leukaemia (B-CLL). Leuk Res 25 (2001) 157-163
27. Menzel T., Rahman Z., Calleja E., et al. Elevated intracellular level of basic fibroblast growth factor correlates with stage of chronic lymphocytic leukemia and is associated with resistance to fludarabine. Blood 87 (1996) 1056-1063
28. Orsini E., and Foa R. Cytokine and regulatory molecules in the pathogenesis and clinical course of B-cell chronic lymphocytic leukemia. In: Cheson B. (Ed). Chronic lymphoid leukemia. 1st edn. (2001), Marcel Dekker, New York 127-159
29. Singhal S., Mehta J., Desikan R., et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341 (1999) 1565-1571
30. Schey S., Fields P., Bartlett J., et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 22 (2004) 3269-3276
31. List A., Kurtin S., Roe D., et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 352 (2005) 549-557
32. Richardson P., Schlossman R., Weller E., et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 100 (2002) 3063-3067
33. Yagyu T., Kobayashi H., Matsuzaki H., et al. Thalidomide inhibits tumor necrosis factor-alpha-induced interleukin-8 expression in endometriotic stromal cells, possibly through suppression of nuclear factor-kappaB activation. J Clin Endocrinol Metab 90 (2005) 3017-3021
34. Mitsiades C., and Mitsiades N. CC-5013 (Celgene). Curr Opin Investig Drugs 5 (2004) 635-647
35. Marriott J., Dredge K., and Dalgleish A. Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agents. Curr Drug Targets Immune Endocr Metabol Disord 3 (2003) 181-186
36. Li X., Liu X., Wang J., et al. Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells. Anticancer Res 23 (2003) 2481-2487
37. Deng L., Ding W., and Granstein R. Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells. J Invest Dermatol 121 (2003) 1060-1065
38. Raje N., and Anderson K. Thalidomide and immunomodulatory drugs as cancer therapy. Curr Opin Oncol 14 (2002) 635-640
39. Hayashi T., Hideshima T., Akiyama M., et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 128 (2005) 192-203
40. Davies F., Raje N., Hideshima T., et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98 (2001) 210-216
41. Dredge K., Marriott J., and Dalgleish A. Immunological effects of thalidomide and its chemical and functional analogs. Crit Rev Immunol 22 (2002) 425-437
42. Anderson K. Lenalidomide and thalidomide: mechanisms of action-similarities and differences. Semin Hematol 42 suppl 4 (2005) S3-S8
43. Dredge K., Horsfall R., Robinson S., et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69 (2005) 56-63
44. Chanan-Khan A., Padmanabhan S., Miller K., et al. In vivo evaluation of immunomodulating effects of lenalidomide on tumor cell microenvironment as a possible underlying mechanism of the antitumor effects observed in patients with chronic lymphocytic leukemia (CLL). Proc Am Soc Hematol vol (2005) 2975 (abstr)
45. Ghobrial I., Bone N., Stenson M., et al. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma. Mayo Clin Proc 79 (2004) 318-325
46. Emilie D., Leger-Ravet M., Devergne O., et al. Intratumoral production of IL-6 in B cell chronic lymphocytic leukemia and B lymphomas. Leuk Lymphoma 11 (1993) 411-417
47. Dredge K., Dalgleish A., and Marriott J. Thalidomide analogs as emerging anti-cancer drugs. Anticancer Drugs 14 (2003) 331-335
48. Corral L., Haslett P., Muller G., et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163 (1999) 380-386
49. Chanan-Khan A., Miller K., Takeshita K., et al. Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood 106 (2005) 3348-3352
50. Chanan-Khan A., Miller K., Marshall P., et al. Thalidomide in combination with fludarabine as initial therapy for patients with treatment naïve chronic lymphocytic leukemia (CLL): preliminary results of a phase I/II clinical trial. Proc Am Soc Hematol vol (2005) 2974 (abstr)
51. Kay N., Geyer S., Yaqoob I., et al. Thalidomide (Td) treatment in chronic lymphocytic leukemia (CLL): a North Central Cancer Treatment Group (NCCTG) study. Proc Am Soc Hematol vol (2003) 5162 (abstr)
52. Furman R., Allen S., Coleman T., et al. Thalidomide alone or in combination with fludarabine are effective treatment for patients with fludarabine-relapsed and refractory CLL. Proc Am Soc Clin Oncol vol (2005) 6640
53. Trompeter S, S DS, Yong K, Jewell A, Nathwani A. Thalidomide in combination with dexamethasone and cyclophosphamide shows activity in patients with relapsed chronic lymphocytic leukaemia. 11th International Workshop on Chronic Lymphocytic Leukemia, Brooklyn, NY, USA 2005; 46: 88 abstr.
54. Wechalekar A., Chen C., Sutton D., et al. Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma. Leuk Lymphoma 44 (2003) 1147-1149
55. Steurer M., Spizzo G., Mitterer M., and Gastl G. Low-dose thalidomide for multiple myeloma: interim analysis of a compassionate use program. Onkologie 27 (2004) 150-154
56. Cheson B., Bennett J., Grever M., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87 (1996) 4990-4997
57. Chanan-Khan A., Miller K., DiMiceli L., et al. Results of phase II study of lenalidomide (Revlimid®) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). Proc Am Soc Clin Oncol vol 6640 (2005) (abstr)
58. Hernandez-Ilizaliturri F., Reddy N., Holkova B., et al. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 11 (2005) 5984-5992
59. Trainor K., Brisco M., Wan J., et al. Gene rearrangement in B- and T-lymphoproliferative disease detected by the polymerase chain reaction. Blood 78 (1991) 192-196
60. DiMiceli L., Miller K., Rickert M., et al. Characterization of IMiDs (immunomodulating agents) induced flare reaction in patients with chronic lymphocytic leukemia (CLL) and correlation with changes in serum cytokine levels. Proc Am Soc Hematol vol (2005) 5049 (abstr)